PMID: 9447427Jan 1, 1997Paper

Vascular dementia: challenge of clinical diagnosis

International Psychogeriatrics
T Erkinjuntti

Abstract

Vascular dementia (VaD) is the second most common cause of dementia. In addition, cerebrovascular diseases (CVD) coexist with other causes of dementia. Cognitive impairment related to CVD may be preventable and these patients could benefit from therapy, which emphasizes the importance of early detection and accurate diagnosis of VaD. The conventional concept of VaD is that of multi-infarct dementia (MID). However, VaD is not only MID; it relates to different vascular mechanisms and different changes in the brain, and has different clinical manifestations with different causes. Critical conceptual questions include the cognitive syndrome and the vascular causes. It is unclear whether the conventional concept of dementia is appropriate or should be substituted with a milder and broader definition, such as vascular cognitive impairment. Furthermore, there is confusion about the causes, especially the role of lesion characteristics and the noninfarct factors. The current diagnostic criteria for VaD are based on the infarct concept. The NINDS-AIREN criteria include dementia, CVD, and a relationship between these two disorders. The criteria define the CVD and the relationship between dementia and CVD, and list supporting clinical fea...Continue Reading

Citations

Nov 23, 2006·Neuroradiology·Ali GuermaziHolly Posner
Nov 6, 2002·Journal of the Neurological Sciences·Kenneth Rockwood
Jul 20, 2001·Archives of Gerontology and Geriatrics·M Dib
May 20, 2000·Annals of the New York Academy of Sciences·V O EmeryJ A Smith
May 7, 2011·Current Gerontology and Geriatrics Research·Rita MorettiGiuseppe Bellini
Jan 22, 2008·Artificial Intelligence in Medicine·Winston H WuWilliam J Kaiser
Oct 5, 2007·IEEE Transactions on Information Technology in Biomedicine : a Publication of the IEEE Engineering in Medicine and Biology Society·Winston H WuWilliam J Kaiser
Mar 12, 2005·Journal of the Neurological Sciences·V Olga EmeryJoseph A Smith
May 28, 2004·Expert Opinion on Pharmacotherapy·Rita MorettiAntonio Bava
Mar 11, 2011·Neuropsychology, Development, and Cognition. Section B, Aging, Neuropsychology and Cognition·James R HallS E O'Bryant
Jan 11, 2008·American Journal of Alzheimer's Disease and Other Dementias·Rita MorettiGilberto Pizzolato
Mar 21, 2006·The Neurologist·Rita MorettiGiuseppe Cazzato
May 15, 2020·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Rita MorettiSilvia Gazzin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Early Markers

Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive cognitive and behavioral decline. Targeting markers in the earliest stages of the disease may mitigate the progression of AD. This feed focuses on early diagnosis and markers, as well as environmental, pharmacological, and drug-response biomarkers associated with this disease.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.

Related Papers

Annals of the New York Academy of Sciences
Koichi OkamotoSusumu Kondo
European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies
Timo Erkinjuntti
European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies
R MorettiG Cazzato
Clinical and Experimental Pharmacology & Physiology. Supplement
H SaitoH Parvez
© 2021 Meta ULC. All rights reserved